Endonovo Therapeutics, Inc. (ENDV) financial statements (2021 and earlier)

Company profile

Business Address 6320 CANOGA AVENUE
WOODLAND HILLS, CA 91367
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 00000
Cash and cash equivalents 00000
Receivables 00   
Other current assets     0
Other undisclosed current assets 0 00 
Total current assets: 00000
Noncurrent Assets
Property, plant and equipment 00000
Intangible assets, net (including goodwill) 345  
Intangible assets, net (excluding goodwill) 345  
Total noncurrent assets: 34500
TOTAL ASSETS: 34500
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 21354
Accounts payable 10   
Accrued liabilities  1   
Interest and dividends payable 1    
Other undisclosed accounts payable and accrued liabilities   354
Debt 76000
Deferred compensation liability 22   
Derivative instruments and hedges, liabilities 114624
Due to related parties 00000
Other undisclosed current liabilities 22521
Total current liabilities: 24151399
Noncurrent Liabilities
Long-term debt and lease obligation 00000
Long-term debt, excluding current maturities 00000
Other undisclosed noncurrent liabilities 00100
Total noncurrent liabilities: 00100
Total liabilities: 241614910
Temporary equity, carrying amount 221  
Stockholders' equity
Stockholders' equity attributable to parent, including: (21)(11)(10)(9)(9)
Preferred stock 000  
Common stock 00000
Common stock, share subscribed but unissued, subscriptions receivable (0)(0)   
Common stock, value, subscriptions   (0)(0)(0)
Additional paid in capital 322420104
Accumulated deficit (53)(36)(29)(18)(13)
Other undisclosed stockholders' equity attributable to parent 00   
Other undisclosed stockholders' equity (2)(2)(1)  
Total stockholders' equity: (22)(13)(10)(9)(9)
TOTAL LIABILITIES AND EQUITY: 34500

Income statement (P&L) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues 00  0
Revenue, net  0
Cost of revenue (0)(0)  (0)
Cost of goods and services sold     (0)
Gross profit: 00  0
Operating expenses (4)(4)(5)(5)(3)
Operating loss: (4)(4)(5)(5)(3)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
 (14)(2)(6)0(4)
Interest and debt expense (0)02(0)(0)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes 0(0)(2)00
Net loss available to common stockholders, diluted: (17)(6)(11)(5)(7)

Comprehensive Income ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss: (17)(6)(11)(5)(7)
Comprehensive loss, net of tax, attributable to parent: (17)(6)(11)(5)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: